Marlborough, Massachusetts — Boston Scientific Corporation reported higher second-quarter sales and earnings, supported by growth across its cardiovascular and medical-surgical businesses.
Net sales for the quarter ended June 30 increased 7.5% to $5.44 billion from $5.06 billion a year earlier. Sales grew 7% on both an operational and organic basis.
Net income attributable to common shareholders rose to $907 million, or 61 cents per share, from $797 million, or 53 cents per share, in the second quarter of 2025. Adjusted earnings increased to 86 cents per share from 75 cents and exceeded the company’s guidance range of 82 cents to 84 cents.
“Our team delivered a solid quarter while continuing to navigate a dynamic environment,” Chairman and Chief Executive Officer Mike Mahoney said. “We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific’s long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.”
Sales in Boston Scientific’s cardiovascular segment increased 8.3% on a reported basis and 7.8% on an operational and organic basis to $3.62 billion.
MedSurg sales rose 5.9% to $1.82 billion. Within the segment, neuromodulation sales increased 12.7% to $341 million, endoscopy sales grew 7.6% to $793 million and urology sales increased 1.1% to $684 million.
Sales in the United States increased 6.2% to $3.43 billion. Revenue rose 11.2% in the Asia-Pacific region, 6.1% in Europe, the Middle East and Africa, and 22.4% in Latin America and Canada.
During the quarter, Boston Scientific completed its previously announced $2 billion accelerated share repurchase program, buying back approximately 40 million shares.
The company also invested $1.5 billion in MiRus LLC for an approximately 34% ownership stake and an exclusive option to acquire its transcatheter aortic valve replacement business. MiRus is developing cardiovascular and orthopedic implants and procedural technologies, including the investigational SIEGEL Balloon Expandable TAVR system.
Boston Scientific presented results from the FRACTURE clinical trial evaluating its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter in patients with severely calcified coronary artery disease. The study met its primary safety and effectiveness endpoints, according to the company.
The company also reported positive results from studies of its pulsed-field ablation technologies for atrial fibrillation. The AVANT GUARD study showed that the FARAPULSE system was statistically superior to anti-arrhythmic drugs in previously untreated patients with persistent atrial fibrillation.
Boston Scientific began enrollment in the pivotal FARADIGM trial evaluating its investigational FARAFLEX Mapping and PFA Catheter in patients with paroxysmal and persistent atrial fibrillation.
The company also received U.S. Food and Drug Administration 510(k) clearance for the TruSelect 2.6 Microcatheter, which is designed to support navigation and embolic delivery during minimally invasive procedures.
Boston Scientific now expects full-year 2026 sales growth of approximately 5.5% to 6.5% on a reported basis and 5% to 6% on an organic basis. Adjusted earnings are projected at $3.28 to $3.32 per share.
For the third quarter, the company expects reported and organic sales growth of 3% to 5% and adjusted earnings of 80 cents to 82 cents per share.
